Skip to content
Doseworth
Menu

FDA warning letter · #716700

Slendid: What the FDA Letter Means for What You Pay

Activesemaglutidetirzepatide
Status

Operating

Concerns

marketing / labeling

Issued

September 2025

Response logged

Not logged

By Marla Whitfield, Pricing Editor

Primary source

Read the original letter on fda.gov →

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/slendid-716700-09092025

What FDA cited

Quoted verbatim from the letter dated

Read the full letter →

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://slendid.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

  1. 1

    The following claim concerning compounded semaglutide and tirzepatide products appears on your website:

  2. 2

    “Clinically proven weight loss treatments”

  3. 3

    Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not.

Process

How a warning letter proceeds

  1. 1

    Letter issued

    September 2025

  2. 2

    15-working-day response window

    FDA gives the company 15 working days to respond in writing.

  3. 3

    Close-out, if issued

    FDA may post one once it is satisfied the cited issues have been corrected.

Is Slendid still operating?

slendid.com returned a live storefront when we checked in August 2026, still selling online GLP-1 prescriptions with a client portal and a published phone number. We did not review every page on the site.

What this means for what you pay

Four words drew this letter, which is the most useful thing about it. "Clinically proven" is doing a specific job in a price comparison: it invites you to treat a cheaper compounded vial and an approved brand as interchangeable, so that the only remaining difference is the number. FDA's point is that the trials behind that phrase were run on the approved product, not on the compounded one you would be buying. That does not mean the medication does not work or that the company misled anyone deliberately — it means the phrase carries more authority than the product behind it has earned. Read the price for what it is, and read "clinically proven" as marketing copy rather than a regulatory status.

Has Slendid responded?

As of , FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Slendid failed to respond.

Sources

Other letters in this index

View the full index →

Editorial disclaimer: An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.